Literature DB >> 23082544

Leishmania infantum infection in two captive barbary lions (Panthera leo leo).

Cédric Libert1, Christophe Ravel, Francine Pratlong, Patrick Lami, Jacques Dereure, Nicolas Keck.   

Abstract

A female barbary lion (Panthera leo leo) from the Montpellier Zoological Park (France) showing colitis, epistaxis, and lameness with pad ulcers was positive by polymerase chain reaction (PCR) for Leishmania infantum. Further indirect immunofluorescence (IFAT) tests on the banked sera from all lions of the park detected another infected but asymptomatic female, which was confirmed by PCR on ethylenediaminetetraacetic acid (EDTA) blood sample. Leishmania infantum zymodeme MON-1 was cultured from EDTA bone marrow samples sampled from this second animal. The first female was successfully treated with marbofloxacine at 2 mg/kg s.i.d. for 28 days (Marbocyl, Vetoquinol 70204 Lure, France) and allopurinol at 30 mg/kg s.i.d. for 3 mo (Allopurinol Mylan, Mylan SAS, 69800 Saint-Priest, France) and then 1 wk/mo. Both positive animals were born at the Rabat Zoological Park, Morocco, and arrived together at Montpellier in 2003. The chronicity and source of this current infection are unknown since Morocco and southern France are well-known to be enzootic for leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23082544     DOI: 10.1638/2012-0056.1

Source DB:  PubMed          Journal:  J Zoo Wildl Med        ISSN: 1042-7260            Impact factor:   0.776


  2 in total

Review 1.  New Epidemiological Aspects of Animal Leishmaniosis in Europe: The Role of Vertebrate Hosts Other Than Dogs.

Authors:  Luís Cardoso; Henk Schallig; Maria Flaminia Persichetti; Maria Grazia Pennisi
Journal:  Pathogens       Date:  2021-03-06

2.  Leishmania infantum in Tigers and Sand Flies from a Leishmaniasis-Endemic Area, Southern Italy.

Authors:  Roberta Iatta; Andrea Zatelli; Pietro Laricchiuta; Matteo Legrottaglie; David Modry; Filipe Dantas-Torres; Domenico Otranto
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.